MAPT and tauopathy: In preclinical stages of AD, BPND (binding potential) of 18F-AV1451 subtly elevated in MAPT mutation carriers (especially R406W) compared to controls, suggesting its use as an early prediction for MAPT mutations that lead to 3R/4R tauopathies [156].